Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16091776 | 0.90 | TLR8 (0.34) | KDM4EALDH1A1NOS2HPGDHSD17B10 | |
| SCHEMBL15629820 | 0.86 | NOS3 (0.42) | KDM4EALDH1A1NOS2HSD17B10NOS3 | |
| SCHEMBL23839498 | 0.78 | MTNR1A (0.34) | KDM4EALDH1A1NOS2HPGDHSD17B10 | |
| SCHEMBL15629846 | 0.77 | NOS3 (0.40) | ALDH1A1NOS2NOS3NOS1POLB | |
| SCHEMBL16091748 | 0.72 | NOS2 (0.37) | KDM4EALDH1A1NOS2HPGDHSD17B10 | |
| SCHEMBL16091768 | 0.71 | KDM4E (0.35) | KDM4EALDH1A1NOS2NOS3NOS1 | |
| SCHEMBL15629824 | 0.69 | POLB (0.34) | NOS2NOS3NOS1POLB | |
| SCHEMBL16091762 | 0.69 | TLR8 (0.35) | KDM4EALDH1A1NOS2HPGDHSD17B10 | |
| SCHEMBL3801326 | 0.69 | SKP2 (0.37) | KDM4EALDH1A1NOS2HPGDHSD17B10 | |
| SCHEMBL15339532 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | GREEN CROSS CORPORATION (KR) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | SLC5A2, SLC5A1, SLC10A2 | KDM4E 767/4885ALDH1A1 691/4885NOS2 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.